Syndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

– NDA submission initiated for revumenib in R/R KMT2Ar acute leukemia under RTOR – – mNPM1 final efficacy data from the Phase 1 portion of AUGMENT-101...

Related Keywords

United States ,American ,Michaela Metzger ,Sharon Klahre ,American Society Of Hematology ,Twitter ,Leukemia Lymphoma Society ,Md Anderson Cancer Center ,Syndax Pharmaceuticals Inc ,Exchange Commission ,Prnewswire Syndax Pharmaceuticals Nasdaq ,Linkedin ,Data Monitoring Committee ,International Number ,Chief Executive ,Pipeline Progress ,Independent Data Monitoring Committee ,American Society ,Annual Meeting ,New Drug Application ,Oncology Review ,Lymphoma Society ,Master Clinical ,Biologics License Application ,Dial In Number ,Private Securities Litigation Reform Act ,Syndax Pharmaceuticals ,Nc ,Pharmaceuticals ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Earnings ,Clinical Trials Amp Medical Discoveries ,